Fineline Cube

Follow:
14691 Articles
CompanyDrug

Zhongsheng Files China Trial Application to Expand Onradivir into High‑Risk Influenza A Patients, Broadening Its First‑in‑Class PB2 Inhibitor Franchise

CompanyDeals

PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases

CompanyDrug

Cutia Therapeutics’ CU‑20101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D
CompanyDeals

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D

CompanyDrug

Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands

CompanyDrug

Hansoh’s HS‑20093 Risvutatug Rezetecan NDA Accepted by NMPA for Small Cell Lung Cancer After First Global Phase III OS Win for a B7‑H3 ADC

CompanyDrug

Ocumension Completes Enrollment in China Phase III Trial of OT‑211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.
CompanyDeals

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

CompanyDeals

HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL‑A830, Its First‑in‑Class KRAS ATTC Cancer Candidate

CompanyDrug

Everest Medicines Wins NMPA Approval for Etripamil Nasal Spray Cardamyst in PSVT, Bringing ER‑Free Arrhythmia Care to Greater China

Policy / Regulatory

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

CompanyDrug

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots